The content on this site is intended for healthcare professionals only
Prof Jean Abraham speaks to ecancer about the phase 3 PARTNER trial.
This trial examines olaparib's effects on wild-type and hereditary breast cancer patients, revealing that it does not improve outcomes for the wild-type group.
In contrast, the hereditary cohort shows improved event-free and overall survival, but no improvement in pathological complete response. The trial was stopped at a planned interim analysis timepoint.
Significant survival rate differences between treatment arms spark discussions on personalised treatment for hereditary breast cancer, with future studies planned to confirm these results and optimise strategies.
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer
Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
Burden and trends of breast cancer worldwide: Opportunities for prevention?
WRN inhibitor shows promise in patients with MSI and/or dMMR advanced solid tumours
Olaparib plus pembrolizumab shows promising results in BRCA mutated cancers
ELCC 2025: Latest in EGFR positive NSCLC
Urine test could reduce post-op scans for kidney cancer by half
Bone-protective agents given with enzalutamide with or without radium-223 show greater survival benefits in mCRPC
